SJEPD030229_D1.RNA-Seq
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- age_years
- 14.13
- fusion
- ZFTA_RELA
- e1_e2
- E1
- umap1_2d
- -1.883090739
- umap2_2d
- 1.481019949
- umap1_3d
- -0.180279339
- umap2_3d
- 3.379109602
- umap3_3d
- -2.998884469
- dataset
- EPN-StJude
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.490
- INTERFERON_GAMMA_RESPONSE+0.420
- PROTEIN_SECRETION+0.420
- ALLOGRAFT_REJECTION+0.410
- APOPTOSIS+0.360
- IL6_JAK_STAT3_SIGNALING+0.320
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.320
- ANDROGEN_RESPONSE+0.300
- PI3K_AKT_MTOR_SIGNALING+0.290
- MITOTIC_SPINDLE+0.250
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.380
- KRAS_SIGNALING_DN-0.260
- WNT_BETA_CATENIN_SIGNALING-0.190
- MYOGENESIS-0.120
- SPERMATOGENESIS-0.100
- UV_RESPONSE_UP-0.090
- HYPOXIA-0.070
- ESTROGEN_RESPONSE_LATE-0.060
- ANGIOGENESIS-0.050
- XENOBIOTIC_METABOLISM-0.050
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934833 | — | — | 0.880 |
| 2 | BS_HBJZR69P | Schwannoma | — | 0.871 |
| 3 | MNG181 | — | — | 0.861 |
| 4 | BS_NR9FRY5T | Schwannoma | — | 0.860 |
| 5 | E5FB107A-9555-419F-84BF-2A59873104B9 | — | — | 0.852 |
| 6 | 9ECB653A-A04F-457C-92FC-D13424511A47 | — | — | 0.852 |
| 7 | B4E10042-052D-4DC4-BC94-FF1D5D4632C0 | — | — | 0.851 |
| 8 | BA28EC2F-5186-4DED-8814-5F0464AB8B87 | — | — | 0.850 |
| 9 | SRR934940 | — | — | 0.850 |
| 10 | SRR934942 | — | — | 0.847 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.490 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.420 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.420 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.410 | Idelalisib | — uncovered |
| APOPTOSIS | 0.360 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.320 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.320 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.290 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.250 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.250 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.240 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.240 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.220 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.210 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.190 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.190 | Idelalisib | — uncovered |
| COMPLEMENT | 0.170 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.170 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.160 | Inavolisib | — uncovered |